Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention is a novel pharmaceutical agent, (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione 1

Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: The present invention provides a compound of formula I 1

Abstract: The sustained release tablet of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) which is disclosed permits twice daily administration of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) to treat humans with Parkinson's disease.

Abstract: A display system for art work includes a molding bracket attached to the top of a wall and a plurality of vertical display units which are attached to and slidable along the molding bracket. Support brackets from which the art works are hung attach to the vertical display units and move vertically along a central track. Preferably, the art work is hung using support bars, which are shaped to fit into the support brackets. Each of the support bars includes a center recess which matches the shape of a slot in the support brackets. When the support bar engages the support bracket, the recess and the slot mate to lock the art work against rotation. The molding bracket and the vertical display units each include a central track, along which the attached units or support brackets move.

Abstract: An improved method and apparatus is provided for the treatment of sewage waste in a long vertical shaft bioreactor wherein waste sewage is caused to circulate under air injected oxidizing conditions around a loop comprising adjacent riser and downcomer chambers connected at their upper and lower ends. The improved method comprises the steps of introducing influent waste at depth into the riser chamber at a point higher in the riser than the point of air injection and withdrawing treated effluent from the riser at a point lower in the riser than the point of air injection. A separation chamber may also be operatively connected to the riser chamber to recover sludge for return to the bioreactor. The method provides an improvement in oxygen uptake rate and reduces the anoxic zone in the reactor thus providing additional capacity for BOD.sub.5 removal.

Abstract: In a long vertical shaft bioreactor for the treatment of degradable wastes in a circulating loop, a process is provided for separating and treating the slowly biodegradable components of the waste. The process comprises the steps of aerating and oxidizing the waste liquor in the reactor to produce an effluent and a foam which foam contains the slowly biodegradable components, which have not been degraded in the oxidizing step, separating and collecting the foam, collapsing the foam and subjecting the collapsed foam to further aeration/oxidation treatment to produce a treated effluent. The thus further treated effluent is returned to the bioreactor for reprocessing.